Literature DB >> 14593091

Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups.

Eric W Fish1, Sara Faccidomo, Sandeep Gupta, Klaus A Miczek.   

Abstract

The S-enantiomer of citalopram, escitalopram, is a selective serotonin reuptake inhibitor (SSRI) that appears to be responsible for citalopram's antidepressant and anxiolytic effects. Clinically, escitalopram is reported to have fewer adverse side effects than do other SSRIs. This study compared escitalopram to other antidepressants in a preclinical procedure predicting anxiolytic-like effects of drugs. Carworth Farms Webster (CFW) mouse pups (7 days old) were separated from the dam and maintained at a temperature of 34 degrees C. Forty-five minutes after administering citalopram (0.56-10 mg/kg), escitalopram (0.0056-3 mg/kg), R-citalopram (1-10 mg/kg), paroxetine (0.3-3 mg/kg), fluoxetine (1-30 mg/kg), or venlafaxine (3-56 mg/kg) subcutaneously, the pups were placed individually on a 19.5 degrees C surface for 4 min. Ultrasonic vocalizations (USVs) (30-80 kHz), grid crossing, rolling (i.e., the pup turned on one side or its back), and colonic temperature were recorded. All the drugs reduced USV emission; escitalopram was the most potent (ED(50) 0.05 mg/kg), followed by paroxetine (0.17 mg/kg), citalopram (1.2 mg/kg), fluoxetine (4.3 mg/kg), R-citalopram (6 mg/kg), and venlafaxine (7 mg/kg). The doses that decreased USVs differed from those that increased motor activity. Increased grid crossing occurred after low doses of paroxetine (0.03 or 0.1 mg/kg) and fluoxetine (1 mg/kg), but only after the highest doses of the citalopram enantiomers and venlafaxine (0.3, 10, and 56 mg/kg, respectively). Except for escitalopram and venlafaxine, high doses of the treatments increased rolling. R-Citalopram caused a 10-fold rightward shift in escitalopram's dose-effect curve, suggesting that R-citalopram inhibits escitalopram's anxiolytic-like effects. These data support clinical findings that escitalopram is a potent, well tolerated SSRI with anxiolytic-like effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14593091     DOI: 10.1124/jpet.103.058206

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  20 in total

1.  Escitalopram in adolescent major depression.

Authors:  James L Schaller; David B Rawlings
Journal:  MedGenMed       Date:  2005-01-31

2.  Screening antidepressants in the chick separation-stress paradigm.

Authors:  Matthew W Feltenstein; Kenneth J Sufka
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

3.  Specific effects of escitalopram on neuroendocrine response.

Authors:  Emily R Hawken; James A Owen; Robert W Hudson; Nicholas J Delva
Journal:  Psychopharmacology (Berl)       Date:  2009-08-07       Impact factor: 4.530

Review 4.  Escitalopram: a review of its use in the management of anxiety disorders.

Authors:  Sohita Dhillon; Lesley J Scott; Greg L Plosker
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.

Authors:  Jacob P R Jacobsen; Per Plenge; Benjamin D Sachs; Alan L Pehrson; Manuel Cajina; Yunzhi Du; Wendy Roberts; Meghan L Rudder; Prachiti Dalvi; Taylor J Robinson; Sharon P O'Neill; King S Khoo; Connie Sanchez Morillo; Xiaodong Zhang; Marc G Caron
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

6.  Long-term citalopram maintenance in mice: selective reduction of alcohol-heightened aggression.

Authors:  Elizabeth E Caldwell; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2007-10-20       Impact factor: 4.530

Review 7.  Social stress, therapeutics and drug abuse: preclinical models of escalated and depressed intake.

Authors:  Klaus A Miczek; Jasmine J Yap; Herbert E Covington
Journal:  Pharmacol Ther       Date:  2008-08-15       Impact factor: 12.310

8.  Fast-scan cyclic voltammetry analysis of dynamic serotonin reponses to acute escitalopram.

Authors:  Kevin M Wood; Parastoo Hashemi
Journal:  ACS Chem Neurosci       Date:  2013-04-24       Impact factor: 4.418

9.  Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups.

Authors:  Aki Takahashi; Jasmine J Yap; Dawnya Zitzman Bohager; Sara Faccidomo; Terry Clayton; James M Cook; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2008-12-20       Impact factor: 4.530

10.  Influence of sex and corticotropin-releasing factor pathways as determinants in serotonin sensitivity.

Authors:  Jonathan G McEuen; Katharine A Semsar; Maria A Lim; Tracy L Bale
Journal:  Endocrinology       Date:  2009-04-02       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.